BioPharma Resources

Drug Trial Radar · NCT07779252

A Study to Assess the Effectiveness and Safety of IPN10200 in Adult Chinese Participants With Moderate to Severe Wrinkle-like Lines Between the Eyebrows

A Phase III, Multicentre, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of IPN10200 in the Improvement of the Appearance of Moderate To Severe Glabellar Lines in Adult Chinese Participants

Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Aug 25, 2026

Primary completion

Apr 10, 2028

Study completion Apr 10, 2028

Sponsor

Lead sponsor
IpsenIndustry
Sponsor type
Industry
First posted
Aug 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out about the effectiveness and safety of a single dose of corabotase (also known as IPN10200) compared to placebo works in participants with moderate to severe glabellar lines. Glabellar lines are wrinkle-like lines that appear between the eyebrows and can become more noticeable with age or repeated facial expressions. They may affect a person's appearance and confidence. In this study, all participants will receive a single injection of either corabotase (the study drug) or placebo. There will be 3 periods in this study: * A screening period (up to 20 days) to assess whether the participant can take part, requiring at least 1 visit to the study centre. * A treatment period (Day 1) where all the eligible participants will receive a single injection of corabotase or placebo. * A follow-up period (52 weeks) where participants' health will be monitored, consisting of regular visits to the study centre and 1 telephone call visit. Participants will undergo health measurements and observation, including blood sampling, physical examinations, and clinical evaluations. They will also be asked to fill in questionnaires and keep a diary. Each participant will be in this study for up to 55 weeks. Participants may withdraw consent to participate at any time.

Conditions

  • Moderate to Severe Glabellar Lines

Interventions

  • CorabotaseBiological

    A single vial of lyophilised powder for solution for injection will be injected locally into several sites across the glabellar region.

  • PlaceboBiological

    A single vial of lyophilised powder for solution, containing excipients without active substance, will be injected locally into several sites across the glabellar region.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants responding to treatmentTime frame: At Week 4

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Peking university first hospital

    Beijing, China · Recruiting

  • Peking Union Medical College Hospital (PUMCH)

    Beijing, China · Not yet recruiting

  • The Third Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China · Not yet recruiting

  • Xiangya School of Medicine at Central South University

    Changsha, Hunan, China · Not yet recruiting

  • Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, China · Not yet recruiting

  • Wuxi People's Hospital

    Wuxi, Jiangsu, China · Recruiting

  • Huashan Hospital Affiliated to Fudan University

    Jing’an, Shanghai Muncipality, China · Not yet recruiting

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China · Not yet recruiting

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.